

Variable Levels of Suppressor Function in Low Density Neutrophils from Patients Receiving Extracorporeal Photopheresis for Chronic Graft Versus Host Disease

N.C. Matthews, P.C. Taylor and A. Alfred. Dept of Photopheresis, Rotherham NHS Foundation Trust, Rotherham, United Kingdom

Introduction

Extracorporeal photopheresis (ECP) is a therapy for steroid-refractory chronic graft versus host disease (cGvHD). Therapeutic response to ECP has been linked with a progressive increase in circulating granulocytic myeloid-derived suppressor cells (G-MDSC) in acute GvHD, but not in cGvHD¹.

1. Low density neutrophils (LDN) phenotypically resembling G-MDSC (putative G-MDSC) show marked flux in cGvHD patients receiving ECP, and a reduction in their frequency is associated with a sustained therapeutic response to ECP².

2. Recent data has identified Lectin-type oxidized LDL receptor-1 (LOX-1) as a specific marker of LDN with T-cell (Tc) suppressive activity³.

3. Using this marker we have conducted a cross-sectional study to assess whether putative G-MDSCs in this patient cohort have suppressive activity.

Materials & Methods

15 patients with steroid refractory or steroid-dependent cGvHD (mean treatment duration of 9 months) receiving ECP and 8 healthy controls were recruited. Patients had GVHD affecting skin (15/15), liver (3/15) and gut (2/15). PBMC were isolated and immunophenotyped by flow cytometry for markers of G-MDSCs (CD14-ve, CD16, CD66b, HLA-DR-ve, CD33int) and LOX-1 expression. Suppressive function was determined by measuring the inhibition of proliferation of anti-CD3/CD28-activated purified CD3 Tc from healthy donors by 4-day co-culture with G-MDSCs from patients. Statistical analysis was conducted using GraphPad 6.

Conclusion

The pattern of LOX-1 expression suggests that only a subset of putative G-MDSCs in ECP patients are suppressive and may explain why suppressive function in this cell fraction is so highly variable. However, the relatively high frequency of LOX-1 cells in this patient cohort might contribute to overall immunosuppression. This requires further investigation.

References

1. Rieber, N. et al. 2014. Bone Marrow Transplantation 49:545-552
2. Matthews, N.C. et al. 2016. Bone Marrow Transplantation 51:S375
3. Condamine, T. et al. 2016. Sci. Immunol 1: aaf8943

Acknowledgements

We thank the patients who kindly donated blood samples for this study, the nursing team – Elizabeth Bacon, Julie Ball, Maggie Foster, Tracy Maher, Janet Mayo, Leah Robertson, Cherie Rushton and Cheryl Swift, Carron Bilton for patient data collection and the Medical Statistics Group, SchARR, University of Sheffield.



European Society for Blood and Marrow Transplantation

Results

ECP patients had substantially greater frequencies of circulating putative G-MDSC than healthy controls (Fig 1A and summarised in Fig 1B: median: 13% and IQR 2%-32% vs 0.2% and IQR 0.1%-0.6%, respectively; $P < 0.0001$). While there were substantially greater frequencies of circulating LOX-1+ cells in PBMC from ECP patients than healthy controls (Fig 2A and summarised in Fig 2B: median: 1.5% and IQR 0.39%-9.2% vs 0.053% and IQR 0.029%-0.062%, respectively; $P < 0.0001$), these were mainly the minority population within the putative G-MDSC fraction with no significant difference between ECP patients and healthy controls in the proportion of LOX-1+ cells within LDN (Fig 2C: 29% +/- 16% vs 21% +/- 9%, respectively). Fig 3A shows that ECP had no significant effect on circulating putative G-MDSC frequency measured before and the day after treatment (median: 8.4% and IQR 4%-44% vs 16% and IQR 6%-25%; $n=11$, respectively) nor on LOX-1 frequency (Fig 3B: median: 1% and IQR 0.29%-12% vs 2.8% and IQR 0.88%-7.3%; $n=9$, respectively). Analysis of suppressive capacity by functional assay shown in Fig 4 demonstrates that at a T-cell:G-MDSC ratio of 1:1, isolated G-MDSCs from ECP patients suppressed CD3 Tc proliferation (mean +/- SD: 52% +/- 23%; $n=14$). However, the potency of suppression was highly variable (min-max: 18%-82%).





Fig 1. (A) Identification of putative G-MDSCs (blue region) in the LDN fraction of PBMC (lymphocytes (red region) and monocytes (green region) from patients with cGvHD. (B) ECP patients ($n=15$) have significantly elevated frequencies of putative G-MDSCs compared to healthy controls ($n=8$). P values calculated by Mann Whitney.





Fig 2 (A) Expression of LOX-1 by LDN from a cGVHD patient undergoing ECP. (B) ECP patients ($n=15$) have elevated frequencies of LOX-1 cells compared to healthy controls ($n=8$). (C) ECP patients ($n=15$) have similar proportions of LOX-1+ cells within LDN compared to healthy controls ($n=8$). P values calculated by Mann Whitney.




Fig 3. No significant effect of ECP on proportions of either (A) LDN in PBMC or (B) LDN expressing LOX-1 ($n=11$ and 9, respectively). Calculated by Wilcoxon's Signed Rank test.




Fig 4. Putative G-MDSCs from ECP patients ($n=14$) have a wide range of ability to suppress activated CD3 T-cells